Airway Improvement with Medium-Term Compression Duration after Right Pulmonary Artery Anterior Translocation

Woo Sung Jang1, Jae Bum Kim1, Jae Hyun Kim1

  • 1Department of Thoracic and Cardiovascular Surgery, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine.

Insights

Left main bronchus compression in a child with cardiac defects was relieved by surgical repair. The procedure successfully addressed airway obstruction caused by a right aortic arch and enlarged pulmonary artery.

Area of Science:

  • Pediatric Cardiology
  • Thoracic Surgery
  • Congenital Heart Disease

Background:

  • Left main bronchus compression is a rare complication in patients with cardiac anomalies.
  • This condition can lead to recurrent respiratory issues, such as pneumonia and desaturation.
  • Congenital heart defects like atrial septal defect (ASD) with a right aortic arch can predispose to airway compression.

Observation:

  • A 19-month-old female presented with recurrent pneumonia and desaturation.
  • The patient had a history of atrial septal defect (ASD) and a right aortic arch.
  • Imaging revealed compression of the left main bronchus by the enlarged right pulmonary artery (RPA) and descending thoracic aorta, present for 14 months.

Findings:

  • Surgical intervention involving ASD closure and anterior translocation of the RPA was performed via sternotomy.
  • The surgical approach successfully relieved the extrinsic compression of the left main bronchus.
  • Symptomatic improvement was noted despite the medium-term duration of bronchial compression.

Implications:

  • Surgical correction of congenital heart defects can effectively resolve associated airway compression syndromes.
  • Early diagnosis and intervention are crucial for managing pediatric patients with cardiac-related bronchopulmonary complications.
  • This case highlights the importance of considering vascular anomalies as a cause of persistent respiratory symptoms in infants.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
630
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
489
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
527
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
642
Cotranslational Protein Translocation01:20

Cotranslational Protein Translocation

Translocation of proteins across membranes is an ancient process that occurs even in bacteria and archaebacteria. In fact, the components of the translocation machinery are still conserved between prokaryotes and eukaryotes.
Sec61 channel partners for cotranslational translocation
During cotranslational translocation, the Sec61 channel partners with the signal recognition particle (SRP), the signal recognition particle receptor (SR), and the ribosomes to transport the nascent polypeptide chain...
10.1K
Energy to Drive Translocation01:37

Energy to Drive Translocation

Mitochondrial protein import is powered by two distinct energy sources: ATP hydrolysis and electrochemical potential across the inner membrane. Newly synthesized precursors are bound by cytosolic chaperones of the Hsp70 family, which guide them to the import receptors on the mitochondrial surface. Utilizing the energy of ATP hydrolysis, Hsp70 chaperones transfer these precursors to the TOM receptors on the mitochondrial outer membrane.
Generally, polypeptides are unfolded by two distinct...
2.9K